Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
NCT07318324Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avutometinib, defactinib and everolimus in endometrial cancer (EC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Adverse Events at 1 year. Started May 2026; status: recruiting.
02
Drugs
avutometinibdefactinibeverolimus
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07318324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318324.